|Mr. Michael A. Martino||CEO & Chairman||585.71k||N/A||1957|
|Ms. Holli Cherevka||Pres & COO||306.59k||N/A||1983|
|Mr. Daniel G. Stokely CPA, CPA||CFO, Corp. Sec. & Treasurer||301.36k||N/A||1964|
|Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D.||Chief Medical Officer||N/A||N/A||1954|
|Lane Hapke||VP of Manufacturing Operations||N/A||N/A||N/A|
|April Ramirez||Clinical Trial Mang.||N/A||N/A||N/A|
|Laura Goldberg||VP of Quality and Regulatory Operations||N/A||N/A||N/A|
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
Ampio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 9. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 4; Compensation: 10.